SORT BY Relevancy
In Clinical Air Episode #12, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer talks with Marc Sluijs, Director Life Science Business Development at Oracle Health Sciences.
Marc shares his thoughts on the digital health space and where technology is heading in clinical trials. In this informal discussion, Craig and Marc also cover how digital technologies can better serve patients as well as tips on keeping tabs on this rapidly moving space and what can disrupt pharma?
Head of Clinical Innovation, R&D
Director Life Science Business Development
Oracle Health Sciences
The Conference Forum
In Clinical Air episode # 8, host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer hosts a show discussing investigators as partners in clinical research. Guests include:
Christine Pierre, President, Society of Clinical Research
Jacalyn Kent, Director, Clinical Development Information & Optimization, Eli Lilly
Key topics include:
Misunderstandings around Remote Based Monitoring
Training and communication challenges for remote site managers
What are the real cost savings around RBM...are we just shifting costs?
Real time data and how this should affect sites and payments
Reducing burdens to the sites
Investigator turn over rate, making sites sustainable
Join host, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion on Investing in the future of clinical research.
Todd Pietri, Co-Founder, Milestone Ventures
Jeremy Sohn, Managing Director, MPM Capital
VC views on:
Disruption in the clinical trial space
Finding opportunities (incubators and accelerators)
Good sources of deal flows
Investing in technology or people?
Beyond the pill
Craig, Todd and Jeremy will also be speaking at Mobile@Dpharm on September 10th at the Farimont Copley Plaza hotel in Boston. This event helps drug developers get their arms around the mobile/digital clinical trial landscape and figure out:
How mobile is innovating clinical trials
What parts of clinical trials mobile/digital technology is currently impacting
How mobile technology is making clinical trials cheaper, easier and more accurate
How mobile/digital is increasing the efficacy of drugs
What the true value is to clinical trials
There is an opportunity to participate in creating a clinical trial app. Mobile@Dpharm will also be of interest to investors and app developers. Following this one day event is DPharm: Disruptive Innovations to Advance Clinical Trials. For more information, visit www.theconferenceforum.org or call 646 350 2580.
Join host, Craig H. Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion on what it really means to partner with patients in clinical trials.
Jeri Burtchell, Founder, Partners in Research
Regina Holliday, Artist and Medical Advocate
For more information on Jeri's new launch, visit: Healthivibe.com and for Regina walking gallary, google Regina Holliday, walking gallary.
For more information on the topic of Patients as Partners, visit www.theconferenceforum.org. The Conference Forum presented a program in March 2014 fully dedicated to understanding the journey a patient takes in clinical trials. Also take a look at Disruptive Innovations to Advance Clinical Trials scheduled for September 11-12, 2014 in Boston. This event addresses significant innovation to help improve a patients experience in a clinical trial.
How a patient experiences a clinical trial is changing. Access, ease, efficiencey, safety and better quality data collection are the target goals. This episode features some of the emerging technologies together with a discussion on the opportunities and challenges to include patient access, recruitment and retention. Predictions for 2014 are shared by our guests.
Craig H. Lipset, MBA
Head of Clinical Innovation, Worldwide Research and Development, Pfizer Inc.
Tomasz Sablinski, MD, PhD
Founder & CEO, Transparency Life Sciences
Senior Director, Product Development, Innovation Lead, Genentech, A Member of the Roche Group, United States
This show is part of the Leukemia & Lymphoma Society Patient Education Series.
Our special guest is Dr. Christopher Yasenchak from Compass Oncology in Portland, Oregon. Dr. Yasenchak received his M.D. from Pennsylvania State University. He continued his training at the Mayo Clinic College of Medicine and is board certified in hematology, medical oncology and internal medicine. His clinical focus is multiple myeloma, lymphoma, stem cell transplantation, gastrointestinal malignancies and clinical trials.
Allison Risha, RN, BSN, OCN, a nursing program coordinator from the Levine Cancer Institute in Charlotte, North Carolina, joins Mike and Joyce to talk about the current state of clinical trials for genitourinary cancers.
Ms. Risha has worked in many aspects of cancer treatment, and is currently a planner and organizer of programs for staff members and patients.
Please join us, and bring your own questions about clinical trials, what they offer beyond standard treatments, and what to think about when considering participation in a clinical trial.
Donald Jones, Chief Digital Officer, Scripps Translational Science Institute talks with host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer on what's happening with digital in drug development. Don discusses his thoughts on the evolution of new products with digital and the “digitazation” of tools for clinical trials. He also shares his thoughts on the biggest disruptors in pharma.
Don and Craig will be featured in an interview as well at DPharm: Disruptive Innovations to Advance Clinical Trials on September 11, 2014 in Boston.
Head of Clinical Innovation, R&D
Chief Digital Officer
Scripps Translational Science Institute
Founder & Chairman, Wireless Life Sciences Alliance
The Conference Forum
This webinar reviews the validation and clinical implementation of BRCAplus, a multi-gene hereditary breast cancer test. Although BRCA1 and BRCA2 account for a large portion of hereditary breast cancer, there are many other genes that differentially impact the risk for breast cancer. BRCAplus was designed to test for mutations in genes that are known to have a high breast cancer risk and that have management guidelines associated with them. With the advent of next-generation sequencing (NGS), it is now possible to test for multiple genes that can increase the risk to develop breast cancer at once.
In 2013 Pfizer launched the Pfizer Blue Button Project, a first-of-it’s-kind initiative enabling patients who have participated in clinical trials the opportunity to download their individual clinical data. Using the Blue Button standard launched by the White House, patients will be empowered to use the data to improve their overall health and wellness, from sharing with healthcare providers to powering clinical risk assessments. In this show, our host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer speaks to the leaders behind these initiatives to find out why they launched, initial learnings, and where the projects may go if successful. Also joining Craig is Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team.
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer
Adam Dole, Presidential Innovation Fellow, The White House
Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team
Jennifer Wulff, Director, Clinical Innovation, Pfizer
Eli Lilly and Quintiles entered into a co-investment partnership to develop a new solution using computer-assisted designs that emphasize the improvement of scientific and operational outcomes of clinical trials. The results were shared at the DPharm 2013 event and project leaders from both companies will talk to our host Craig Lipset on how this formation is doing a year later. Also joining Craig is Jeff Lee, CEO, Omniscience to discuss featured news and trends in clinical trial innovation and in particular mobile applications.
Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer, Inc.
Jeffrey Kasher, PhD, VP & COO, Eli Lilly & Company
Jeff Lee, CEO, Omniscience Mobile
Rick Sax, MD, SVP Clinical Design & Reporting Services, Quintiles
MIRAI CLINICAL | The Scent of Youth: Japan (March 24, 2014) - Mirai Clinical is introducing recent Japanese personal hygiene advances to the American market. It is common knowledge that an unpleasant odor is frequently noticed in nursing homes. This odor, sometimes referred to as "aging odor" or “old people smell”, has been incorrectly attributed to improper facilities cleaning, or incontinence and other ailments of the patients. The problem is particularly irksome in Japan, which has a culture of cleanliness. The minerals and water from our sweat are a fertile environment for bacterial growth, which is the source of traditional body odor noticed when we do not bathe adequately. Separately, the lipid acids we secrete "oxidize" with oxygen in the air, and transform into a different compound, which produces it's own odor. The researchers who discovered the phenomenon named the stale smelling compound "Nonenal (no-nay-nal)".
ABOUT MIRAI CLINICAL: Mirai Clinical Executive and Product Management is an International team comprised of experienced skin care and medical professionals from Japan and the U.S. Their mission is to develop the most ground-breaking, naturally safe and exceptionally effective products for body care and skin health. Mirai, which means “the future” or “new beginning,” issymbolic of this mission in introducing breakthrough, innovative skin care technology based on science and nature.Mirai Clinical Website: www.MiraiClinical.com
Join Host Live Chats
- Carlotta Chatwood (9 chatters)
- Destruindo Fortalezas (6 chatters)
- ADR CoXHost (5 chatters)
- churchfolk (4 chatters)
- Callywood (4 chatters)
- Psychic Choice Radio (4 chatters)
- Red River Radio (4 chatters)
- RevBarbara (3 chatters)
- Talking Smooth Jazz (3 chatters)
- Top Star Hip Hop Radio (3 chatters)
- MUTHA WIT WISDOM (2 chatters)
- Do ChimeIn (2 chatters)
- babycoaldust (1 chatters)
- Barry Secrest (1 chatters)
- Brother Dave0137 (1 chatters)
- Our Own Voices Live (1 chatters)
- Simon Barrett (1 chatters)
- Rev Deb (1 chatters)
- NDB Media Sports Channel (0 chatters)
- Latrivia Nelson (0 chatters)